LONDON, Aug 4 (Reuters) - London-listed group Shire said it was seeking to buy Baxalta in a $30 billion all-share deal, going public with its bid to create a global specialist in rare diseases after the U.S. firm spurned its initial approach.
from Reuters: New Issues News http://ift.tt/1IJJxal
Tidak ada komentar:
Posting Komentar